New Approach Methodologies (NAMs): By the numbers
We outline today’s animal-use landscape, the rise of NAMs, & how the Non-Animal Navigator supports…
CertaraDecember 10, 2025
New Approach Methodologies: Redefining Animal Testing Alternatives
Explore how New Approach Methodologies (NAMs) and advanced in silico and in vitro tools are…
CertaraDecember 10, 2025
A Guide to the FDA Announcement to Phase Out Animal Testing for Drugs
The FDA is phasing out animal testing of new drugs. Learn how Certara’s Non-Animal Navigator™…
CertaraNovember 17, 2025
Certara Study Shows Half of Americans Unaware of FDA/NIH Move to Phase Out Animal Testing of New Drugs
Certara’s new survey findings show that 50% of Americans are unaware of FDA and NIH…
CertaraNovember 12, 2025
Towards new approach methodologies for biological therapeutics: a novel model-informed metric to assess immunogenicity risk
Immunogenicity poses a significant challenge in biotherapeutics development due to the formation of anti-drug antibodies…
Danielle PillsburyNovember 7, 2025
In silico Safety and Toxicology assessment: ToxStudio®
Discover how Certara’s ToxStudio align with FDA’s roadmap to reduce animal testing and transform preclinical…
CertaraOctober 30, 2025
Move Away From Animal-Only Testing May Improve, Speed Rare Disease Research
The article, "Move Away From Animal-Only Testing May Improve, Speed Rare Disease Research," explores a…
Danielle PillsburySeptember 10, 2025
AI-driven drug discovery picks up as FDA pushes to reduce animal testing
AI is revolutionizing drug discovery and safety testing as drug developers adopt these technologies in…
CertaraSeptember 9, 2025
How Pharma Can Transition to Non-animal Studies for Investigational Drugs
Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…
CertaraJuly 25, 2025
